Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • Patent number: 11166974
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: November 9, 2021
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20210330654
    Abstract: A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
    Type: Application
    Filed: June 25, 2021
    Publication date: October 28, 2021
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko KIRIHARA, Atsushi SHIMAZAKI, Masatsugu NAKAMURA
  • Patent number: 11090296
    Abstract: The present invention relates to an ophthalmic depot preparation comprising benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide, wherein the volume ratio of benzyl benzoate and/or benzyl alcohol to polyethylene glycol and/or dimethylsulfoxide in the ophthalmic depot preparation is 75:25 to 25:75, and the total amount of benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide contained is 50% (w/w) or more.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: August 17, 2021
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Komei Okabe, Toyomi Fujisawa, Kazuhito Yamada
  • Publication number: 20210228700
    Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.
    Type: Application
    Filed: April 13, 2021
    Publication date: July 29, 2021
    Applicants: ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yasufumi MURAKAMI, Shigeki MUKOUBATA, Hirotada AKIYAMA, Koji KONOMI
  • Publication number: 20210178080
    Abstract: According to some embodiments, a syringe may include a barrel; a delivery conduit; a plunger seal disposed within the barrel; and a plunger rod assembly affixed to an end of the barrel, the plunger rod assembly including a first plunger rod component comprising a first linear gear, a second plunger rod component disposed at least partially in the barrel and engaged with the plunger seal, wherein the second plunger rod component comprises a second linear gear, a first rotational gear having a plurality of gear teeth for engaging the first linear gear, and a second rotational gear having a second plurality of gear teeth for engaging the second linear gear, wherein the first rotational gear is coupled to the second rotational gear such that translation of the first plunger rod component causes translation of the second plunger rod component.
    Type: Application
    Filed: April 7, 2017
    Publication date: June 17, 2021
    Applicants: Santen Pharmaceutical Co., Ltd., Congruence Medical Solutions, LLC
    Inventors: Gautam N. SHETTY, Lou CASTAGNA
  • Patent number: 11013731
    Abstract: The present disclosure relates to methods of treating prostate cancer by administering an effective amount of sirolimus locally to the prostate of a subject in need thereof. In particular, the present disclosure provides methods of treating prostate cancer by intratumoral injection of a liquid formulation comprising sirolimus in which the amount of sirolimus administered is well above the dosage used for preventing transplant rejection.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: May 25, 2021
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Aishwarya Kundu, Cecile Escudero, Sreenivasu Mudumba
  • Patent number: 11007259
    Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: May 18, 2021
    Assignees: ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yasufumi Murakami, Shigeki Mukoubata, Hirotada Akiyama, Koji Konomi
  • Patent number: 11008387
    Abstract: An object of the present invention is to provide an antibody against VEGF that inhibits binding of a vascular endothelial growth factor (VEGF) to neuropilin-1 (NRP1). The present invention provides an antibody against VEGF that inhibits binding of VEGF to NRP1.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: May 18, 2021
    Assignees: ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yasufumi Murakami, Hiroyuki Satofuka, Shigeki Mukoubata, Hirotada Akiyama, Tatsuji Kurose, Sae Akao
  • Publication number: 20210128601
    Abstract: An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Yoshihiro OSHITA, Hitoshi NAKAZAWA, Isao MATSUOKA, Asuka KAMIMURA
  • Publication number: 20210128492
    Abstract: The present invention provides a novel composition for preventing and/or improving brain dysfunction comprising a lutein or a salt thereof and a plant product of the genus Trapa as active ingredients, particularly a composition for use as a pharmaceutical product and a food and beverage.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 6, 2021
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Takeshi ITO, Hideto MAEDA, Sachiko HAYASHI, Yuri SAWANO, Tomoaki NANRI
  • Publication number: 20210106569
    Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining omidenepag and ripasudil or netarsudil, each complement and/or enhances the intraocular pressure lowering effect. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.
    Type: Application
    Filed: December 20, 2018
    Publication date: April 15, 2021
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro FUWA, Takazumi TANIGUCHI
  • Patent number: 10940144
    Abstract: The present invention aims to find a novel pharmaceutical use of omidenepag, esters thereof, or salts thereof. The present inventors have made intensive studies to find a novel pharmaceutical use of omidenepag, an ester thereof, or a salt thereof, and have found as a result that omidenepag, an ester thereof, or a salt thereof significantly dilates retinal blood vessels, and significantly increases blood flow. Therefore, omidenepag, an ester thereof, or a salt thereof is expected to protect retinal nerve cells and be useful for prevention and/or treatment of ophthalmic diseases involving retinal nerve cell disorder.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 9, 2021
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takazumi Taniguchi, Takahiro Akaishi, Hitoshi Nakazawa
  • Publication number: 20210059931
    Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Applicants: Santen Pharmaceutical Co., Ltd., AGC Inc.
    Inventors: Timo REUNAMAKI, Pertti PELLINEN, Olli OKSALA, Kari LEHMUSSAARI
  • Publication number: 20210059997
    Abstract: Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.
    Type: Application
    Filed: December 27, 2018
    Publication date: March 4, 2021
    Applicants: UNIVERSITY OF FUKUI, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masaya OKI, Fumito KANADA, Kazuma KAMATA, Yoshihiro TAKAMURA, Seiji MIYAKE, Masaru INATANI, Hiroyuki UCHIDA, Miho NOGATA, Masatomo KATO, Koushi FUJISAWA, Shinji TAKAOKA
  • Patent number: 10918656
    Abstract: An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: February 16, 2021
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro Oshita, Hitoshi Nakazawa, Isao Matsuoka, Asuka Kamimura
  • Publication number: 20210011004
    Abstract: A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Application
    Filed: September 28, 2020
    Publication date: January 14, 2021
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA
  • Publication number: 20210000844
    Abstract: Provided is an ophthalmic composition comprising diquafosol or a salt thereof and a cationic polymer, the cationic polymer being at least one selected from the group consisting of chitosan, a chitosan derivative, a cationic (meth)acrylate copolymer, a cationic silicone polymer, a diallyl quaternary ammonium salt-acrylamide copolymer, cationic hydrolyzed keratin, cationic hydrolyzed silk, cationic hydrolyzed collagen, cationic hydrolyzed casein, cationic hydrolyzed soy protein, a cationic vinylpyrrolidone copolymer, polyvinylpyrrolidone, a dimethyldiacrylammonium chloride homopolymer, an adipic acid-dimethylaminohydroxypropyldiethylenetriamine copolymer, an adipic acid-epoxypropyldiethylenetriamine copolymer and an acrylamide-?-methacryloyloxyethyltrimethylammoniummethyl sulfate copolymer.
    Type: Application
    Filed: February 27, 2019
    Publication date: January 7, 2021
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Kyohei TAKAHASHI, Hiroyuki ASADA, Asuka KAMIMURA, Kenji MORISHIMA, Yusuke MOMOKAWA, Kenichi ENDO
  • Patent number: 10864159
    Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: December 15, 2020
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., AGC INC.
    Inventors: Timo Reunamaki, Pertti Pellinen, Olli Oksala, Kari Lehmussaari
  • Publication number: 20200383957
    Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
    Type: Application
    Filed: May 19, 2020
    Publication date: December 10, 2020
    Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
  • Publication number: 20200352852
    Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
    Type: Application
    Filed: April 27, 2020
    Publication date: November 12, 2020
    Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE